Evidence map›Paper›PMID 42640729›Full record

ArticleThe Journal of clinical investigation2026

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Vlad Moisoiu, Roxanne Lourman, Frank Szulzewsky, Tobias Kessler, Giulio Collotta, Antonio Porro, Anne Bertolini, Franziska Singer, Patrick J Cimino, Caroline Hertler and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Vlad MoisoiuDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Roxanne LourmanDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Frank SzulzewskyDepartment of Neurosurgery, Clinical Neurosciences Center and.
Tobias KesslerClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Giulio CollottaInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Antonio PorroInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Anne BertoliniNEXUS Personalized Health, ETH Zurich, Zurich, Switzerland and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Franziska SingerNEXUS Personalized Health, ETH Zurich, Zurich, Switzerland and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Patrick J CiminoBrain Tumor Institute, Center for Cancer and Immunology Research, Children's National Research Institute, Washington, DC, USA.
Caroline HertlerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Wolfgang WickClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University and University Hospital Düsseldorf, Düsseldorf, Germany.
Eric C HollandHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Alessandro A SartoriInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Hans-Georg WirschingDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<strong>A prime resistance mechanism of glioblastoma to temozolomide is a vulnerability to radiation therapy</strong>.

Indexed as

Brain NeoplasmsDNA-Binding ProteinsGlioblastomaMutS Homolog 2 ProteinRadiation ToleranceAnimalsDacarbazineHumansMiceTemozolomideDacarbazineDNA-Binding ProteinsG-T mismatch-binding proteinMSH2 protein, humanMutS Homolog 2 ProteinTemozolomideBrain cancerGeneticsOncology

Identifiers

PMID42640729
PMCPMC13626850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.